Pharmaron (03759) has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility.

The company's board has resolved and approved the adoption of the 2026 H-Share Award Plan, with a plan limit set at 28 million H-shares. The share source for the plan includes treasury H-shares repurchased by the company from time to time, as well as newly issued H-shares. The primary objective is to fully mobilize employee initiative and creativity, effectively enhance core team cohesion and corporate competitiveness, and promote the company's sustained, stable, and high-quality development.

The 2026 H-Share Award Plan is expected to be effective for a period of 10 years from its adoption date. Its terms will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The plan will only take effect after it is approved by a resolution of the company's shareholders.

To facilitate the implementation of the 2026 H-Share Award Plan, the board will also propose granting a share repurchase authorization to the shareholders. This authorization will be used, among other purposes, to execute the 2026 H-Share Award Plan, and to authorize the board and its delegates to manage the plan.